half-life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-15 and is reviewed periodically as new material appears.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
== Modern Development: Sector 13 == For decades, Manimajra sat outside Chandigarh's formal grid because the city's planner, Le Corbusier, omitted the number 13 due to superstition. Following long-standing demands from residents in upscale enclaves like the Modern Housing Complex (MHC) and Shivalik Enclave, the area was officially integrated into the sectoral grid as Sector 13 in February 2020. This change was enacted by Governor V.P. Singh Badnore under the Capital of Punjab Act of 1952.
Among other contributions, his research introduced oncocin, a novel antimicrobial peptide optimized for treating Gram-negative bacteria, showing effective activity and improved stability in mouse serum without causing lysis or toxicity. Later, he showed that LL-37 acts through pore formation in membranes made of unsaturated lipids whereas it yields membrane modulation in saturated lipids, suggesting new design strategies for antimicrobial peptide drugs.
Max Bergmann (12 February 1886 – 7 November 1944) was a Jewish-German biochemist. Together with Leonidas Zervas, the discoverer of the group, they were the first to use the carboxybenzyl protecting group for the synthesis of oligopeptides.
PGC1-α (PPARGC1A), a transcriptional coactivator of nuclear receptors important to the regulation of a number of mitochondrial genes involved in oxidative metabolism, directly interacts with MEF2 to synergistically activate selective slow twitch (ST) muscle genes and also serves as a target for calcineurin signaling. A peroxisome proliferator-activated receptor δ (PPARδ)-mediated transcriptional pathway is involved in the regulation of the skeletal muscle fiber phenotype. Mice that harbor an activated form of PPARδ display an "endurance" phenotype, with a coordinated increase in oxidative enzymes and mitochondrial biogenesis and an increased proportion of ST fibers. Thus—through functional genomics—calcineurin, calmodulin-dependent kinase, PGC-1α, and activated PPARδ form the basis of a signaling network that controls skeletal muscle fiber-type transformation and metabolic profiles that protect against insulin resistance and obesity. The transition from aerobic to anaerobic metabolism during intense work requires that several systems are rapidly activated to ensure a constant supply of ATP for the working muscles. These include a switch from fat-based to carbohydrate-based fuels, a redistribution of blood flow from nonworking to exercising muscles, and the removal of several of the by-products of anaerobic metabolism, such as carbon dioxide and lactic acid. Some of these responses are governed by transcriptional control of the fast twitch (FT) glycolytic phenotype.
Maximinus Thrax, Roman emperor (c. 173, reigned 235–238). Descriptions, as well as depictions, indicate acromegaly, though remains of his body are yet to be found. Lorenzo de' Medici (1449–1492) may have had acromegaly. Historical documents and portraits, as well as a later analysis of his skeleton, support the speculation. Sergei Rachmaninoff (1873–1943), pianist and composer, who was noted for his hands that could comfortably stretch a thirteenth on the piano. He was not diagnosed with acromegaly in his lifetime, but a medical article from 2006 suggests that he might have had it. Adam Rainer (22 February 1899 – 4 March 1950), Austrian man who is the only person in recorded history to have been both a dwarf and a giant. He is believed to have had acromegaly.[51]
Sources: en.wikipedia.org
=== Associated conditions === Sjögren's disease is associated with a number of other medical conditions, many of which are autoimmune or rheumatic disorders, such as celiac disease, fibromyalgia, systemic lupus erythematosus (lupus), autoimmune thyroiditis, multiple sclerosis and spondyloarthropathy, and several malignancies, principally non-Hodgkin lymphoma. Sjogren's is the second most common cause of dysautonomia.
== History == Scott Reismanis, a website developer from Melbourne, Australia, first pursued web development as a hobby, creating two websites dedicated to video games. Afterwards, he purchased the ChaosRealm.com domain and formed the Realm Network. The network comprised over twenty websites, one of which was ModDB's predecessor, ModRealm. Launched in 1998, ModRealm was initially dedicated to Counter-Strike cheat codes before becoming a modding website. The website became defunct in December 2001, when its network was shut down after its hosting service, Playnet, filed for bankruptcy. Reismanis was motivated to start a new website by the difficulty of searching for mods on the then-dominant search engine, AltaVista, much less mods released to the public. He began ModDB's development in January 2002, following IMDb's structure in the process. The website was launched as Mod Database in June 2002. It differed from his earlier websites in that its articles were managed by the community, not only the website's founder. By January 2005, ModDB listed 49,539 members and 2,191 mods. In 2006, the ModDB team launched AddonDB, whose aim was to list additional content for games not applicable under the category of game modifications. This includes models, skins and maps. Just one year into service, it was merged into ModDB.
=== Archers and Custodians of Dawn and Twilight === Kaya Fugeki (巫覡 花矢, Fugeki Kaya) The Archer of Dawn, her task is to bring the Day to Yamato. She is a 16 y/o high school student with a masculine way of speech, but no one knows she's the Goddess of the Day, except Yuzuru. She deeply cares for Yuzuru. She tries to force him to abandon his role as Guardian so that he can gain the freedom she lacks. Yuzuru Fugeki (巫覡 弓弦, Fugeki Yuzuru) The Archer of Dawn's Custodian. He decided to serve Kaya in place of his father. He is proud of his work and is fond of Kaya, but is annoyed that she is trying to force him to abandon his role as her Custodian. Kaguya Fugeki (巫覡 輝矢, Fugeki Kaguya) The Archer of Twilight, his task is to bring Night to Yamato. He fell into depression after his wife and his custodian, Eken, suddenly ran away from home. His feelings for Tsukihi are difficult to explain in words. Eken Fugeki (巫覡 慧剣, Fugeki Eken) The Archer of Twilight's Custodian. He respects Kaguya and they once lived together as father and son, but one day, he ran away.
238Pu due to its much shorter half life heats up to much higher temperatures and glows red hot with blackbody radiation if left without external heating or cooling. This heat has been used in radioisotope thermoelectric generators (see below). The resistivity of plutonium at room temperature is very high for a metal, and it gets even higher with lower temperatures, which is unusual for metals. This trend continues down to 100 K, below which resistivity rapidly decreases for fresh samples. Resistivity then begins to increase with time at around 20 K due to radiation damage, with the rate dictated by the isotopic composition of the sample. Because of self-irradiation, a sample of plutonium fatigues throughout its crystal structure, meaning the ordered arrangement of its atoms becomes disrupted by radiation with time. Self-irradiation can also lead to annealing which counteracts some of the fatigue effects as temperature increases above 100 K. Unlike most materials, plutonium increases in density when it melts – by 2.5% – but the liquid metal exhibits a linear decrease in density with temperature. Near the melting point, the liquid plutonium has very high viscosity and surface tension compared to other metals.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.